PUK17 Pharmacoeconomic Analysis Of Everolimus Immunosupressive Therapy After Renal Transplantation  by Avxentyeva, M et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A511
reached the therapeutic target set by the K/DOQI Guidelines (P< 5.5 mg/dL). The 
economic evaluation was conducted according to the hospital perspective and were 
considered the only consumption associated with the purchase of the drugs admin-
istered. Results: The combination of LC plus standard therapy has produced a 
significant increase in the percentage of patients who achieved the target range as 
defined by the K/DOQI Guidelines (+85.16%). The reduction of 21.2 mg/dL (-32.7%) 
mean phosphorus in FP (4,55 mg/dL) than in the FR (6.77 mg/dL) was statistically 
significant (p < 0.001). The average expected cost/year for patients treated with LC 
plus standard therapy (€ 2,527.88) was higher of € 419.60 (+ 16.6%) compared to the 
standard therapy alone (€ 2,108.28). The analysis of cost-effectiveness showed an 
incremental cost per patient to therapeutic target of € 492.69 for LTS compared to 
TS (projected annual cost). ConClusions: The introduction of the LC in the treat-
ment of hemodialysis patients with uncontrolled hyperphosphatemia is very cost-
effective and has allowed a significant increase in the achievement of therapeutic 
targets with minimal increase in costs for the National Health System.
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objeCtives: Nocturia is defined by the International Continence Society as the 
complaint of ‘waking to void 1 or more times a night followed by sleep’. The most 
common cause is nocturnal polyuria (NP - nocturnal urine overproduction). While 
recognised as bothersome, it is often under-recognised as a separate condition and 
thus treated by medications for overactive bladder (OAB) or benign prostate hyperpla-
sia (BPH), and not by an antidiuretic recommended for hormonal/renal dysfunctions, 
for example desmopressin. This analysis investigates the potential under-treatment 
of nocturia in a real world setting. Methods: Data were drawn from a 2013 cross-
sectional survey of physicians and consulting patients. Primary care physicians (264) 
and urology specialists (371) in France, Germany, Spain, UK and USA, actively manag-
ing urology patients, completed patient record forms prospectively for the next 14 
OAB/BPH/nocturia patients who consulted. Results: Physicians provided records 
on 8738 patients, of which 569 had a primary diagnosis of nocturia or NP. There was 
substantial variation in treatment: 46% received an OAB treatment, 16% a BPH treat-
ment, 7% other treatments, 21% no treatment, and 16% received desmopressin. There 
was considerable frequency in switching to second or third line treatments. After 
a mean of 16 months, 132 of the nocturia patients (23%) switched to a new treat-
ment. Among these, 19% switched again after 13 months. Nocturia patients receiving 
desmopressin at some point were more likely to be satisfied with, and continue their 
current treatment, compared to those on BPH or OAB medications. ConClusions: 
The real-world survey suggests nocturia treatment is far from optimal in view of the 
need to frequently switch treatment modalities offering distinctly differing pharma-
codynamic actions. Prescribing bladder or prostate medications for a renal condition, 
or withholding treatment, could potentially lead to considerable drug waste, extra 
physician visits, delay of most appropriate treatment and impaired quality of life.
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objeCtives: Nocturia (getting up at night to void) can have a negative impact on 
quality of life (QoL), but limited data are available to determine the size of this impact. 
This study aimed to derive utility data on the impact of nocturia on QoL from the 
randomised clinical trial CS29 (clinicaltrials.gov; NCT00477490) for desmopressin ver-
sus placebo. Methods: SF-12 data collected at three time-points in CS29 (n= 803, 
male= 434, female= 369) were mapped to utility values using the SF-6D. Multiple data 
points were available per patient; a mixed model, with patient as a random effect 
variable, was therefore fitted using the generalised additive mixed model procedure in 
R. Utilities were produced accounting for the difference in various potentially clinical 
significant factors: age, body mass index, gender, number of co-morbidities, number 
of voids (NOV) and time to first void (TTV, also called first uninterrupted sleep period - 
FUSP). Diagnostic plots were produced to test model fit (scatter, residual and Q-Q), and 
Spearman rank correlations were calculated for all pairwise comparisons to test for 
multicollinearity in the data. For calculation of predictive utilities, all variables were 
set to their median values. Results: All diagnostic plots showed a good model fit 
and no violation of model assumptions. Though multicollinearity was found between 
NOV (median= 3.33 voids) and TTV (median= 1.78h), both variables were kept in the 
model to determine their relative impact on QoL. Both NOV and TTV had a significant 
impact on utility, with up to 0.1 change in score. The utility was 0.75, 0.72 and 0.69 
for [0;2[, [2;4[ and [4;+∞[ voids per night, respectively. Age presented with the lowest 
utility score for patients aged 40-50. Male patients had a higher score than female 
patients. ConClusions: Nocturia severity has a significant impact on QoL. NOV and 
TTV can cause changes up to 0.1 in utility score.
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objeCtives: LUTS (lower urinary tract symptoms) are highly frequent and bother-
some to the patient. Nocturia, defined by the International Continence Society as 
4mg. The resulting incremental cost effectiveness ratio (ICER) was € 15,388/QALY 
gained. The probability of mirabegron 50 mg/day being cost-effective relative to 
tolterodine 4mg/day was 81.9% at a willingness to pay threshold of € 30,000/QALY. 
Incremental cost-effectiveness ratios of mirabegron 50mg/day versus solifenacin 
5 and 10 mg/day were € 2,536 and € 4,837 per QALY gained, respectively. The prob-
ability of cost effectiveness for mirabegron 50mg/day was 90.0% and 90.5% versus 
solifenacin 5 and 10 mg/day respectively. Mirabegron 50mg/day was the dominant 
treatment (more effective with lower costs) versus fesoterodine 4 and 8 mg/day with 
a probability of cost-effectiveness of 93.8% and 93.1%, respectively. ConClusions: 
Mirabegron 50 mg/day is a cost-effective treatment compared with antimuscarin-
icagents in OAB patients from a Spanish NHS perspective.
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bACkgRound: Immunosuppresive therapy after organ transplantation is financed 
from federal budget in Russia, but only when certain drugs are prescribed, i.e. 
mycophenolic acid, mycophenolate mofetil, cyclosporine, tacrolimus. Everolimus 
had demonstrated good efficacy and safety in renal transplantation patients but has 
not been included into federal drug provision program yet. objeCtives: to calculate 
cost difference between two approaches for immunosuppressive therapy after renal 
transplantation: everolimus plus reduced-exposure cyclosporine (Ev+Cyc_red) and 
mycophenolic acid plus standard-exposure cyclosporine (MA+Cyc_st) for Russian 
healthcare system. Methods: We calculated the two-year difference in costs that 
resulted from efficacy and safety differences of compared alternatives employing 
the probability model. Data on safety and efficacy of compared strategies were 
taken from D. Cibrik et al. randomized control trial (2013). Direct medical costs were 
calculated from the Russian healthcare system point of view. We also estimated 
the 5-year budget impact of everolimus inclusion into the drug provision program 
financed from federal budget. Results: Ev+Cyc_red leads to cost reduction by € 2.5 
thousands (17%) per patient in a two-year period when compared to MA+Cyc_st. The 
reduction mainly results from less costs for immunosuppressive drugs in Ev+Cyc_
red approach compared to MA+Cyc_st. Also costs for cytomegalovirus infection 
prevention and treatment are smaller in Ev+Cyc_red strategy. Everolimus inclu-
sion into federal drug provision program will lead to reduction in federal budget 
spending starting from the first year; the total five-year budget savings are € 4.3 
million. ConClusions: Ev+Cyc_red is a cost-saving option for immunosuppres-
sive therapy after renal transplantation in Russia when compared with MA+Cyc_st.
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objeCtives: Laparoscopic surgery is commonly used to remove the kidney 
from a donor in kidney transplant but was recently used for the first time in the 
UK to implant the kidney. The objective of this study was to analyse the cost-
effectiveness of using laparoscopic surgery compared to open surgery in kidney 
recipients. Methods: A decision tree model with a time-horizon of 10 days was 
constructed to capture short-term costs and benefits of patients undergoing kidney 
transplantation. The model was built from a third-party payer perspective in the UK. 
The costs for work-up, surgery, blood transfusion during surgery, equipment, hospi-
tal stay and post-operative complications were informed by National Health Service 
reference costs and published literature. The utilities for a patient during surgery 
(0.00), during recovery (0.48), with complications after surgery (0.40) and after being 
released from hospital (0.84) were derived from published literature. Results: The 
total costs for the laparoscopic surgery arm were lower than those for open sur-
gery arm (£25,891 versus £25,962) – although the laparoscopic procedure itself was 
more expensive, the costs were offset by savings from reduced blood loss and lower 
risk of complications. The total quality adjusted life years (QALYs) were higher for 
laparoscopic surgery (0.01718 versus 0.01369) because of the lower number of days 
needed for recovery. At a threshold of £20,000 per QALY, the probability that laparo-
scopic surgery is cost effective was 0.595. The key drivers of the model were lengths 
of hospital stay after open and laparoscopic surgery and duration of laparoscopic 
surgery. The incremental cost effectiveness ratio was dominant in the base case but 
could be as high as £78,468 if risk of complications after open surgery decreases from 
0.512 to 0.368. ConClusions: This study suggests that the laparoscopic surgery 
improves quality of life at a lower cost, but is subject to uncertainty.
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objeCtives: The objective of this study is to evaluate the difference in terms of 
efficacy and costs of lanthanum carbonate plus standard therapy (LTS) compared 
to standard therapy alone (TS) in the treatment of hemodialysis patients with 
persistent hyperphosphatemia. Methods: We selected 14 consecutive patients 
(8 males and 7 females) on hemodialysis with more than four phosphorus values 
greater than 6 mg/dL in three months, got them recruited in therapy with lantha-
num carbonate. The data analysis has been done considering a phase retrospective 
(FR) of three months and a phase perspective (FP) of six months, analyzing for each 
subject consumption and the effectiveness of therapy before and after enrollment. 
The effectiveness of treatment, was evaluated as the percentage of patients who 
